Jeffrey Capello
Director/Board Member chez NEOGEN CORPORATION
Fortune : - $ au 31/03/2024
Profil
Jeffrey D.
Capello is the founder of Monomoy Advisors LLC, which was founded in 2021.
He is currently serving as the Managing Member of Monomoy Advisors LLC.
Additionally, Mr. Capello holds current positions as an Independent Director at Neogen Corp.
since 2022 and at Agios Pharmaceuticals, Inc. since 2023.
In his former roles, Mr. Capello served as a Director at Sirtris Pharmaceuticals, Inc. in 2008, an Independent Director at Flex Pharma, Inc. from 2015 to 2018, and as an Independent Director at OvaScience, Inc. He also held the position of Chief Financial Officer & Executive Vice President at Boston Scientific Corp.
from 2010 to 2013, at Biogen, Inc. from 2018 to 2020, and at Revvity, Inc. from 2001 to 2008.
Prior to that, he was a Partner at PricewaterhouseCoopers LLP from 1997 to 2001 and served as the Chief Financial Officer & Executive Vice President at Ortho-Clinical Diagnostics, Inc. in 2014.
Mr. Capello completed his undergraduate degree at the University of Vermont and holds an MBA from Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NEOGEN CORP
-.--% | 26/10/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Jeffrey Capello
| Sociétés | Poste | Début |
|---|---|---|
| NEOGEN CORPORATION | Director/Board Member | 12/09/2022 |
| AGIOS PHARMACEUTICALS, INC. | Director/Board Member | 01/06/2023 |
Anciens postes connus de Jeffrey Capello
| Sociétés | Poste | Fin |
|---|---|---|
| BIOGEN INC. | Director of Finance/CFO | 15/08/2020 |
Flex Pharma, Inc.
 Flex Pharma, Inc. Pharmaceuticals: MajorHealth Technology Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA. | Director/Board Member | 06/06/2018 |
Ortho-Clinical Diagnostics, Inc.
 Ortho-Clinical Diagnostics, Inc. Medical SpecialtiesHealth Technology Ortho-Clinical Diagnostics, Inc. engages in the manufacture and design of diagnostic, transfusion, clinical equipment, and systems. It provides solutions for screening, diagnosing, monitoring, and confirming diseases early before they put lives at risk. Its products include instrument systems and reagents that screen for AIDS and hepatitis C, as well as blood typing systems. The company was founded in 1939 and is headquartered in Raritan, NJ. | Director of Finance/CFO | 12/06/2015 |
| BOSTON SCIENTIFIC CORPORATION | Director of Finance/CFO | 31/12/2013 |
Formation de Jeffrey Capello
| University of Vermont | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| NEOGEN CORPORATION | Health Technology |
| BOSTON SCIENTIFIC CORPORATION | Distribution Services |
| BIOGEN INC. | Health Technology |
| REVVITY, INC. | Health Technology |
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
Sirtris Pharmaceuticals, Inc.
 Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | Health Technology |
OvaScience, Inc.
 OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Health Technology |
Ortho-Clinical Diagnostics, Inc.
Ortho-Clinical Diagnostics, Inc. Medical SpecialtiesHealth Technology Ortho-Clinical Diagnostics, Inc. engages in the manufacture and design of diagnostic, transfusion, clinical equipment, and systems. It provides solutions for screening, diagnosing, monitoring, and confirming diseases early before they put lives at risk. Its products include instrument systems and reagents that screen for AIDS and hepatitis C, as well as blood typing systems. The company was founded in 1939 and is headquartered in Raritan, NJ. | Health Technology |
Flex Pharma, Inc.
Flex Pharma, Inc. Pharmaceuticals: MajorHealth Technology Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA. | Health Technology |
